Article Information
History
- January 5, 2022.
Article Versions
- Version 1 (December 16, 2021 - 13:31).
- Version 2 (December 20, 2021 - 09:37).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Subramanian Pushkala1,
- Sudha Seshayyan1,
- Ethirajan Theranirajan2,
- Doraisamy Sudhakar2,
- Kadalraja Raghavan3,
- Vidyasagar Devaprasad Dedeepiya4,
- Nobunao Ikewaki5,6,
- Masaru Iwasaki7,
- Senthilkumar Preethy8 and
- Samuel JK Abraham4,7,9,*
- 1Department of Immunology, The Tamil Nadu Dr. M.G.R. Medical University, Chennai, 600032, India
- 2Rajiv Gandhi Government General Hospital, Madras Medical College, Chennai, Tamil Nadu, India
- 3Dept of Paediatric Neurology, Jesuit Antonyraj memorial Inter-disciplinary Centre for Advanced Rehabilitation and Education (JAICARE), Madurai, India
- 4Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
- 5Dept. of Medical Life Science, Kyushu University of Health and Welfare, Japan
- 6Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan
- 7Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of Medicine, Chuo, Japan
- 8Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
- 9Antony-Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd., Kofu, Japan
- ↵*Corresponding author information:
Dr. Samuel JK Abraham, II Department of Surgery & CACR, University of Yamanashi, Faculty of Medicine, Address for correspondence: 3-8, Wakamatsu, Kofu, 400-0866, Yamanashi, Japan, Email id- drsam{at}nichimail.jp; Alternate email id: drspp{at}nichimail.jp, Fax: +81-55-235-7569
Posted January 05, 2022.
Efficient control of IL-6, CRP and Ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective clinical trial
